Developing a new treatment using live bacteria for ulcerative colitis
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis
This study is testing a new treatment that uses good bacteria from your body to help reduce gut inflammation for people with ulcerative colitis and Crohn's disease, aiming to improve your gut health with fewer side effects than current options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rise Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Rockville, UNITED STATES) |
| Project ID | NIH-10894064 on NIH RePORTER |
What this research studies
This research aims to create a novel Live Biotherapeutic Product (LBP) that utilizes the body's natural microbiome to reduce inflammation in the gut, specifically targeting ulcerative colitis and Crohn's disease. The approach focuses on restoring the intestinal barrier and regulating immune responses to improve gut health. By leveraging beneficial bacteria, the treatment seeks to provide a safer alternative to current therapies, which often have significant side effects. Patients participating in this research may receive a new form of therapy that could help manage their condition more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with ulcerative colitis or Crohn's disease.
Not a fit: Patients with other gastrointestinal disorders or those who are not diagnosed with inflammatory bowel disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment option for patients suffering from ulcerative colitis, potentially improving their quality of life.
How similar studies have performed: While the use of live biotherapeutics is an emerging field, previous studies have shown promise in utilizing microbiome-based therapies for inflammatory conditions, indicating potential success for this approach.
Where this research is happening
Rockville, UNITED STATES
- Rise Therapeutics, LLC — Rockville, United States (Active)
Researchers
- Principal investigator: Fanger, Gary — Rise Therapeutics, LLC
- Study coordinator: Fanger, Gary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.